Kura Oncology

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Kura Oncology (KURA) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Kura Oncology (KURA) Looks Good: Stock Adds 6.8% in Session

SAN DIEGO, Aug.  25, 2020  (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced the appointment of Stephen Dale, M.D., as Chief Medical Officer. Dr. Dale joins Kura most recently from Kyowa Kirin, where he served as Senior Vice President and Global Head of Medical Science with a primary focus in oncology.

Kura Oncology Appoints Dr. Stephen Dale as Chief Medical Officer

Kura Oncology, Inc. (KURA) CEO Troy Wilson on Q2 2020 Results - Earnings Call Transcript

SAN DIEGO, Aug.  04, 2020  (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation at the 2020 Wedbush PacGrow Healthcare Virtual Conference. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to present an overview of the company on Tuesday, August 11, 2020 at 2:20 p.m. ET / 11:20 a.m. PT. The virtual conference will be held from August 11-12, 2020.

Kura Oncology to Present at Wedbush PacGrow Healthcare Virtual Conference

SAN DIEGO, July  30, 2020  (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that it will report second quarter 2020 financial results after the close of U.S. financial markets on Thursday, August 6, 2020. Kura’s management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update.

Kura Oncology to Report Second Quarter 2020 Financial Results

SAN DIEGO, June  11, 2020  (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the JMP Securities Hematology & Oncology Forum (Virtual). Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a fireside chat on Thursday, June 18, 2020 at 10:40 a.m. ET / 7:40 a.m. PT. The virtual forum will be held from June 18-19, 2020.

Kura Oncology to Participate in JMP Securities Hematology & Oncology Forum

– Oral presentation to highlight clinical data for tipifarnib in HRAS mutant solid tumors, including overall survival data in head and neck squamous cell carcinoma – – Oral presentation to highlight clinical data for tipifarnib in HRAS mutant solid tumors, including overall survival data in head and neck squamous cell carcinoma –

Kura Oncology Announces Three Abstracts Accepted for Presentation at ASCO20 Virtual Scientific Program

SAN DIEGO, May  06, 2020  (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the pricing of an underwritten public offering of 9,100,000 shares of its common stock at a price to the public of $13.75 per share. The gross proceeds to Kura from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Kura, are expected to be approximately $125.1 million. In addition, Kura has granted the underwriters a 30-day option to purchase up to an additional 1,365,000 shares of common stock. The offering is expected to close on or about May 8, 2020, subject to customary closing conditions.

Kura Oncology Announces Pricing of $125 Million Public Offering of Common Stock

Kura Oncology, Inc. (KURA) CEO Troy Wilson on Q1 2020 Results - Earnings Call Transcript

Kura Oncology is riding the coattails of another clinical-stage biopharmaceutical company.

Why Kura Oncology Is Skyrocketing Today

– Second Fast Track designation for tipifarnib further highlights potential for tipifarnib to address unmet need for patients –

Kura Oncology Receives Fast Track Designation for Tipifarnib in T-Cell Lymphomas

Kura Oncology, Inc. (KURA) CEO Troy Wilson on Q4 2019 Results - Earnings Call Transcript

– Dr. Antonio Gualberto to step down after enabling multiple registrational strategies for tipifarnib, positioning program for success –

Kura Oncology Announces Transition of Chief Medical Officer

Company strengthens leadership team to support pre-commercial efforts and launch optimization Company strengthens leadership team to support pre-commercial efforts and launch optimization

Kura Oncology Appoints Kirsten Flowers as Chief Commercial Officer

– Fast Track designation highlights potential for tipifarnib to address unmet need for patients with HRAS mutant HNSCC –

Kura Oncology Receives Fast Track Designation for Tipifarnib in HRAS Mutant HNSCC and Provides Enrollment Guidance for AIM-HN Trial

– Tipifarnib demonstrates robust and durable activity as a monotherapy in advanced AITL, an aggressive form of T-cell lymphoma –

Kura Oncology Reports Clinical and Regulatory Updates for Tipifarnib in Angioimmunoblastic T-Cell Lymphoma

Kura Oncology Should Be On Your Radar With Upcoming Presentation For Cancer Study

Kura Oncology, Inc. (KURA) CEO Troy Wilson on Q3 2019 Results - Earnings Call Transcript

– Former Biogen senior counsel brings more than 20 years of combined in-house and law firm experience – – Former Biogen senior counsel brings more than 20 years of combined in-house and law firm experience –

Kura Oncology Appoints James Basta as Chief Legal Officer

– 56% confirmed ORR in 18 efficacy-evaluable HNSCC patients with HRAS mutant variant allele frequency ≥ 20% –

Kura Oncology Reports Durable Anti-Tumor Activity in Phase 2 Trial of Tipifarnib in HRAS Mutant Head and Neck Cancer

– Data from Phase 2 clinical trial of tipifarnib in HRAS mutant HNSCC selected for short-talk during Spotlight on Proffered Papers session on Tuesday, October 29th –

Kura Oncology Data Selected for Oral Presentation at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

SAN DIEGO, Oct.  16, 2019  (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that an abstract related to the Company’s Phase 2 clinical trial of tipifarnib in HRAS mutant head and neck squamous cell carcinomas (HNSCC) has been accepted for presentation at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, which will be held from October 26-30, 2019 in Boston. Details are as follows:

Kura Oncology Announces Upcoming Presentation at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

– Accomplished executive adds extensive experience in launching novel therapies as Company sets sights on commercial readiness – – Accomplished executive adds extensive experience in launching novel therapies as Company sets sights on commercial readiness –

Kura Oncology Expands Board of Directors with Appointment of Diane Parks

– KO-539 is a first-in-class small molecule inhibitor of the menin-MLL interaction –

Kura Oncology Doses First Patient in Phase 1 Clinical Trial of Menin-MLL Inhibitor KO-539 in Acute Myeloid Leukemia

– Confirmed objective responses achieved in five of 13 evaluable patients –

News for Kura Oncology Stock (KURA)